524 related articles for article (PubMed ID: 24138713)
1. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
5. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
8. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
De Luca A; Normanno N
Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Westover D; Zugazagoitia J; Cho BC; Lovly CM; Paz-Ares L
Ann Oncol; 2018 Jan; 29(suppl_1):i10-i19. PubMed ID: 29462254
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
[TBL] [Abstract][Full Text] [Related]
15. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG; Shih JY
Mol Cancer; 2018 Feb; 17(1):38. PubMed ID: 29455650
[TBL] [Abstract][Full Text] [Related]
16. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
17. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
Ricciuti B; Baglivo S; De Giglio A; Chiari R
Ther Adv Respir Dis; 2018; 12():1753466618808659. PubMed ID: 30355049
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Lin CC; Yang JC
Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
[TBL] [Abstract][Full Text] [Related]
20. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Lovly CM; Horn L
Curr Treat Options Oncol; 2012 Dec; 13(4):516-26. PubMed ID: 22833206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]